<DOC>
	<DOCNO>NCT01937312</DOCNO>
	<brief_summary>The purpose study demonstrate additive effect brinzolamide 1 % /brimonidine 0.2 % ( SIMBRINZA® suspension ) subject either open angle glaucoma ocular hypertension currently prostaglandin analogue ( PGA ) monotherapy .</brief_summary>
	<brief_title>Effect SIMBRINZA® Suspension Added Therapy Prostaglandin Analogue</brief_title>
	<detailed_description>This study divide 2 sequential phase . The Screening/Eligibility Phase include one Screening Visit two Eligibility Visits , subject washed intraocular pressure ( IOP ) -lowering medication dose TRAVATAN Z® , XALATAN® , LUMIGAN® , 1 drop instill eye daily 28 day . Subjects meet inclusion/exclusion criterion randomize second Eligibility Visit . The Treatment Phase consist two on-therapy visit ( Week 2 Week 6 ) .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<criteria>Diagnosis open angle glaucoma ( include openangle glaucoma pseudoexfoliation pigment dispersion ) ocular hypertension ; Mean intraocular pressure ( IOP ) measurement least 1 eye ( study eye ) ≥ 21 mmHg &lt; 32 mmHg 2 consecutive visit ( Eligibility 1 Eligibility 2 ) ; Previously prescribe TRAVATAN Z® 0.004 % , XALATAN® 0.005 % , LUMIGAN® 0.01 % monotherapy least 28 day prior Screening Visit ; Able understand sign Informed Consent Document ; Other protocoldefined inclusion criterion may apply . Women childbearing potential pregnant , breastfeeding , agree use adequate birth control method throughout study ; Any form glaucoma open angle glaucoma ocular hypertension ; Severe central visual field loss ; Chronic , recurrent , severe inflammatory eye disease ; Ocular trauma within past 6 month ; Ocular infection ocular inflammation within past 3 month ; Bestcorrected visual acuity score worse approximately 20/80 Snellen ; Eye surgery within past 6 month ; Any condition , include severe illness , would make subject unsuitable study opinion Investigator ; Use additional topical systemic ocular hypertensive medication study ; Patients , opinion Investigator , discontinue IOPlowering ocular medication ( ) per appropriate washout schedule prior Eligibility 1 Visit ; Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>glaucoma</keyword>
	<keyword>prostaglandin analogue</keyword>
	<keyword>brinzolamide</keyword>
	<keyword>brimonidine</keyword>
</DOC>